A model of persistent post SARS-CoV-2 induced lung disease for target identification and testing of therapeutic strategies.
Dinnon KH 3rd, Leist SR, Okuda K, Dang H, Fritch EJ, Gully KL, De la Cruz G, Evangelista MD, Asakura T, Gilmore RC, Hawkins P, Nakano S, West A, Schäfer A, Gralinski LE, Everman JL, Sajuthi SP, Zweigart MR, Dong S, McBride J, Cooley MR, Hines JB, Love MK, Groshong SD, VanSchoiack A, Phelan SJ, Liang Y, Hether T, Leon M, Zumwalt RE, Barton LM, Duval EJ, Mukhopadhyay S, Stroberg E, Borczuk A, Thorne LB, Sakthivel MK, Lee YZ, Hagood JS, Mock JR, Seibold MA, O'Neal WK, Montgomery SA, Boucher RC, Baric RS.
Dinnon KH 3rd, et al. Among authors: seibold ma.
bioRxiv [Preprint]. 2022 Feb 15:2022.02.15.480515. doi: 10.1101/2022.02.15.480515.
bioRxiv. 2022.
PMID: 35194605
Free PMC article.
Preprint.